Ipsen (OTCMKTS:IPSEY) Stock Passes Above 200 Day Moving Average – What’s Next?

Ipsen S.A. (OTCMKTS:IPSEY)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $30.55 and traded as high as $31.66. Ipsen shares last traded at $31.27, with a volume of 9,037 shares changing hands.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada raised Ipsen from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 16th.

Ipsen Stock Up 0.1 %

The firm’s 50 day simple moving average is $30.34 and its 200 day simple moving average is $30.56.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.